• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
HCM

HCM

HUTCHMED (China) Limited

NASDAQHealthcareDrug Manufacturers - Specialty & GenericHK

USD11.31

-0.21 (-1.82%)

Rating:C-

Company Profile

CEO

Chig Fung Cheng

IPO Date

2016-03-16

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

HK

Market Metrics

Open

$11.52

Prev. Close

$11.52

Day Low

$11.17

Day High

$11.52

52W Low

$11.10

52W High

$19.50

Market Cap

$1.97B

Volume

0.10M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

32.1%

Avg Negative

2.1%

Avg Neutral

66.0%

News Feed

Health Care, BioTech Are Highly Regulated Globally: Hutchmed

Bloomberg Markets and Finance·7/29/2021·↑ positive

HUTCHMED Reports 2021 Interim Results and Provides Business Updates

GlobeNewsWire·7/28/2021·↑ positive

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer

GlobeNewsWire·7/27/2021·↑ positive

Stabilizing Actions and End of Stabilization Period in connection with the Global Offering

GlobeNewsWire·7/23/2021·↓ negative

Hutchmed's Stock Rises After EMA Validates Surufatinib Application For Neuroendocrine Tumors

Benzinga·7/16/2021·↑ positive

HUTCHMED's Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

GlobeNewsWire·7/15/2021·↑ positive

HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca

GlobeNewsWire·7/13/2021·↑ positive

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering

GlobeNewsWire·7/12/2021·↑ positive

HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China

GlobeNewsWire·7/5/2021·↑ positive

HUTCHMED to Announce 2021 Half-Year Financial Results

GlobeNewsWire·7/2/2021·↓ negative